NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
Clinical Trials
132 trialsNCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT00923806 2026-01-23
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT06337630 2026-01-02
POP-ART
Institut Curie
Phase 1 Terminated
NCT06523803 2025-10-21
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Zymeworks BC Inc.
Phase 1 Terminated
NCT05646797 2025-10-20
A Study of ASP2074 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Terminated
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05490043 2025-08-29
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Corporation
Phase 1 Terminated
NCT06877533 2025-08-12
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Terminated
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05904236 2025-04-08
ICVB-1042
IconOVir Bio
Phase 1 Terminated
NCT05429762 2025-04-06
TusaRav-QT
Sanofi
Phase 1 Terminated
NCT01529593 2025-03-24
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02187848 2025-02-10
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05781360 2024-12-20
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04528836 2024-12-12
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Navire Pharma Inc., a BridgeBio company
Phase 1 Terminated
NCT05198349 2024-11-25
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono
Phase 1 Terminated
NCT05601830 2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
NCT03783403 2024-09-19
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
Phase 1 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT05631327 2024-05-28
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Terminated
NCT04250597 2024-05-06
Study of GNX102 in Patients With Advanced Solid Tumors
GlycoNex, Inc.
Phase 1 Terminated
NCT04349280 2024-04-18
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT03604445 2024-03-04
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Terminated
NCT03416816 2023-11-14
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1 Terminated
NCT04729725 2023-08-14
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03333031 2023-06-18
A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
Duke University
Phase 1 Terminated
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02452268 2023-03-03
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis
Phase 1 Terminated
NCT00293215 2022-10-10
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02801097 2022-05-17
PAYLOAD
EpicentRx, Inc.
Phase 1 Terminated
NCT04009460 2022-04-29
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Terminated
NCT02571530 2021-11-03
Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
Northwell Health
Phase 1 Terminated
NCT02168725 2021-06-22
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Terminated
NCT02291614 2021-03-16
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
Amgen
Phase 1 Terminated
NCT02244112 2021-02-21
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Amgen
Phase 1 Terminated
NCT03096340 2020-12-22
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Intezyne Technologies, Inc.
Phase 1 Terminated
NCT01240642 2020-12-09
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
Novartis
Phase 1 Terminated
NCT01278758 2020-12-09
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Novartis
Phase 1 Terminated
NCT01278849 2020-12-09
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
Novartis
Phase 1 Terminated
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT03295942 2020-08-11
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1 Terminated
NCT02271516 2020-07-30
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
National Atomic Research Institute, Taiwan
Phase 1 Terminated
NCT01358331 2020-04-02
MK-8353-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00684294 2020-03-02
Auto TAG
Mary Crowley Medical Research Center
Phase 1 Terminated
NCT02540291 2020-02-17
Study of E7046 in Subjects With Selected Advanced Malignancies
Eisai Inc.
Phase 1 Terminated
NCT02630251 2020-02-12
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
GlaxoSmithKline
Phase 1 Terminated
NCT00028652 2019-12-13
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
University of Wisconsin, Madison
Phase 1 Terminated
NCT02134197 2019-12-11
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
Bayer
Phase 1 Terminated
NCT03494231 2019-07-30
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Henlix, Inc
Phase 1 Terminated